Singapore, June 26 -- Mubadala Bio has announced the signing of a licencing and supply agreement with Biosidus, a leading biotechnology company in Argentina, at the BIO International Convention 2026 in San Diego, US. The agreement will be executed through DiabTec, Mubadala Bio's biologics facility in the UAE and marks an important step in the company's efforts to expand access and availability of advanced biologic medications in the country.

The partnership is expected to support the localisation of several important biologics used in the treatment of a range of conditions across endocrinology, nephrology and oncology, reinforcing Mubadala Bio's mission to strengthen national drug security.

Abu Dhabi has emerged as one of the few places...